Papers - Matsumoto, Kazuaki

Factorial analysis of hepatitis B virus reactivation-induced hepatitis B using JADER.

Ayako Hara, Kazuaki Matsumoto, Yuta Yokoyama, Junko Kizu.

BIOLOGICAL & PHARMACEUTICAL BULLETIN (PHARMACEUTICAL SOC JAPAN)  40 ( 6 ) 782 - 788 2017.06

Research paper (scientific journal), Joint Work, Accepted,  ISSN  0918-6158

　View Summary

Hepatitis B caused by chemotherapy- and immunosuppression-associated hepatitis B virus reactivation is likely to become fulminant, and a high mortality rate has been reported. In this study, using the Japanese adverse drug event report database (JADER), factorial analysis of patients who developed hepatitis B as an adverse event was performed. The number of reported cases of hepatitis B during the survey period was 781 and 185 of them (24%) died. Rituximab and prednisolone were administered to many cases (233, 216 cases, respectively), and the reporting odds ratios were high (65.35, 13.40, respectively), suggesting their strong association with the development of hepatitis B. Regarding the onset time, rituximab-induced hepatitis B developed within one year after administration in 83%, being a high frequency. Prednisolone-induced hepatitis B developed even after one year in 36%. Since prednisolone is used to treat rheumatoid arthritis at a dose <= 10mg/d, the patients were divided based on the prednisolone dose into the groups treated at >10 and <= 10 mg/d, and the onset time was investigated in each group. The median onset time was 113 and 330d, respectively, showing a significant difference. On time-to-event analysis using the Weibull distribution, rituximab was classified as the early failure type, and prednisolone and methotrexate for rheumatoid arthritis were classified as the wear out failure type. These findings are important information which may lead to early discovery of and taking actions against hepatitis B being helpful for providing appropriate medical care.

ラモトリギンの医薬品副作用データおよび医薬品副作用被害救済給付決定情報の調査解析.

横山雄太, 黒田裕子, 安藤剛, 松元一明, 木津純子.

日本病院薬剤師会雑誌 53   283 - 289 2017.03

Research paper (scientific journal), Joint Work, Accepted,  ISSN  1341-8815

抗菌薬のTDM実施に関する実態調査－TDM実施率と感染制御体制との関連性およびTDMの実施方法の抗菌薬TDMガイドラインとの比較－.

松元一明, 磯田梨奈, 黒田裕子, 横山雄太, 木津純子.

日本化学療法学会雑誌 65   175 - 182 2017.03

Research paper (scientific journal), Joint Work, Accepted,  ISSN  1340-7007

Synthesis of linezolid metabolites PNU-142586 and PNU-142300 toward the exploration of metabolite-related events.

Kengo Hanaya, Kazuaki Matsumoto, Yuta Yokoyama, Junko Kizu, Mitsuru Shoji, Takeshi Sugai.

CHEMICAL & PHARMACEUTICAL BULLETIN 65   194 - 199 2017.02

Research paper (scientific journal), Joint Work, Accepted,  ISSN  1347-5223

有害事象自発報告データベース（JADER）からみた医薬品による交通事故.

安藤剛, 松元一明, 横山雄太, 木津純子.

日本交通科学協議会誌 16   46 - 51 2017.01

Research paper (scientific journal), Joint Work, Accepted,  ISSN  13469282

CYP2C19遺伝子多型と代謝物濃度をふまえたTDMによるボリコナゾール投与量適正化が有用であった2例.

茂見茜里, 松元一明, 渡辺英里香, 猪川和朗, 金澤直子, 横山雄太, 梅﨑雄太, 池田龍二, 森川則文, 武田泰生

日本外科感染症学会雑誌 13   661 - 667 2016.12

Research paper (scientific journal), Joint Work, Accepted,  ISSN  1349-5755

Pregabalin prescription for terminally ill cancer patients receiving specialist palliative care in an acute hospital.

Ryo Yajima, Kazuaki Matsumoto, Yuya Ise, Norihito Suzuki, Yuta Yokoyama, Junko Kizu, Shiro Katayama.

JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES 2   29 2016.11

Research paper (scientific journal), Joint Work, Accepted,  ISSN  2055-0294

Pharmaceutical studies on and clinical application of olanzapine suppositories prepared as a hospital preparation.

Kazuaki Matsumoto, Satoru Kimura, Kenichi Takahashi, Yuta Yokoyama, Masayuki Miyazawa, Satoko Kushibiki, Morio Katamachi, Junko Kizu.

JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES 2   20 2016.09

Research paper (scientific journal), Joint Work, Accepted,  ISSN  2055-0294

The pharmacokinetics of ampicillin-sulbactam in anuric patients: dosing optimization for prophylaxis during cardiovascular surgery.

Yuta Yokoyama, Kazuaki Matsumoto, Kazuro Ikawa, Erika Watanabe, Hiroyuki Yamamoto, Yutaka Imoto, Norifumi Morikawa, Yasuo Takeda.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACY 38   771 - 775 2016.08

Research paper (scientific journal), Joint Work, Accepted,  ISSN  2210-7711

医薬品副作用被害救済制度からみた抗菌薬が関連した副作用被害の実態.

佐藤沙紀, 松元一明, 黒田裕子, 木津純子.

日本化学療法学会雑誌 64   656 - 662 2016.07

Research paper (scientific journal), Joint Work, Accepted,  ISSN  1340-7007

Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data.

Kazuaki Matsumoto, Kazuko Abematsu, Akari Shigemi, Naoko Kanazawa, Erika Watanabe, Yuta Yokoyama, Kazuro Ikawa, Norifumi Morikawa, Yasuo Takeda.

JOURNAL OF CHEMOTHERAPY 28   198 - 202 2016.06

Research paper (scientific journal), Joint Work, Accepted,  ISSN  1120-009X

抗菌薬TDMガイドライン2016.

竹末芳生, 大曲貴夫, 岡田賢二, 笠原敬, 関雅文, 髙倉俊二, 高橋佳子, 時松一成, 松元一明, 三鴨廣繁, 猪川和朗, 平田純生, 木村利美, 小林昌宏, 西圭史, 浜田幸宏.

日本化学療法学会雑誌 64   387 - 477 2016.05

Research paper (scientific journal), Joint Work, Accepted,  ISSN  1340-7007

Pharmacokinetics and brain penetration of carbapenems in mice.

Kazuaki Matsumoto, Yuji Kurihara, Yuko Kuroda, Seiji Hori, Junko Kizu.

JOURNAL OF INFECTION AND CHEMOTHERAPY 22   346 - 349 2016.04

Research paper (scientific journal), Joint Work, Accepted,  ISSN  1341-321X

Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections.

Kazuaki Matsumoto, Erika Watanabe, Naoko Kanazawa, Tomohide Fukamizu, Akari Shigemi, Yuta Yokoyama, Kazuro Ikawa, Norifumi Morikawa, Yasuo Takeda.

CLINICAL PHARMACOLOGY: ADVANCES AND APPLICATIONS 8   15 - 18 2016.03

Research paper (scientific journal), Joint Work, Accepted,  ISSN  1179-1438

自動車運転に影響を及ぼす医薬品の処方における薬局薬剤師の対応.

髙橋佑介, 松元一明, 黒田裕子, 大原整, 木津純子.

日本交通科学協議会誌 15 ( 3 ) 29 - 37 2016.03

Research paper (scientific journal), Joint Work, Accepted,  ISSN  13469282

A bundle that includes active surveillance, contact precaution for carriers, and cefazolin-based antimicrobial prophylaxis prevents methicillin-resistant Staphylococcus aureus infections in clean orthopedic surgery.

Hideki Kawamura, Kazuaki Matsumoto, Akari Shigemi, Michiyo Orita, Aya Nakagawa, Tomoko Nozima, Hiroyuki Tominaga, Setsuro Komiya, Koichi Tokuda, Junichiro Nishi.

AMERICAN JOURNAL OF INFECTION CONTROL (MOSBY-ELSEVIER)  44 ( 2 ) 210 - 214 2016.02

Research paper (scientific journal), Joint Work, Accepted,  ISSN  0196-6553

　View Summary

Background: Methicillin-resistant Staphylococcus aureus (MRSA) is a frequent cause of orthopedic surgical site infections (SSIs). The aim of this study was to evaluate the effect of a bundle approach in the prevention of orthopedic MRSA SSIs.
Material and Methods: MRSA active surveillance and decolonization were performed preoperatively at our institution from July 2004 until 2007. In January 2008, a bundle approach comprising contact precautions for MRSA-positive patients and cefazolin-based antimicrobial prophylaxis (AMP) stewardship was implemented. Data on the prevalence of MRSA SSIs, antimicrobial use density, duration of AMP, and the use of an alcohol antiseptic agent (L/1,000 patient-days) were evaluated during 2 periods: July 2004-December 2007 (period A) and January 2008-December 2012 (period B).
Results and Discussion: The MRSA SSI rate during period B (0.97%; 19 out of 1,966) was significantly lower than that during period A (2.17%; 29 out of 1,333; P =.003). The infection rate correlated negatively with both the cefazolin antimicrobial use density (r = -0.76; P = .0002) and the use of an alcohol antiseptic agent (r = -0.68; P = .002).
Conclusions: An infection-prevention bundle consisting of contact precautions for carriers and AMP stewardship in addition to active surveillance was associated with a significant decrease in the incidence of orthopedic MRSA SSIs. Copyright (c) 2016 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

• Access to Document (DOI)

フレーバー添加レバミピド内用液剤の安定性に関する基礎検討.

矢島領, 今岡楓太, 輪湖哲也, 黒田裕子, 松元一明, 木津純子, 片山志郎.

YAKUGAKU ZASSHI 135   1397 - 1402 2015.12

Research paper (scientific journal), Joint Work, Accepted,  ISSN  0031-6903

Anti-inflammatory effects of linezolid on carrageenan-induced paw edema in rats.

Kazuaki Matsumoto, Shigeaki Obara, Yuko Kuroda, Junko Kizu.

JOURNAL OF INFECTION AND CHEMOTHERAPY (Elsevier)  21 ( 12 ) 889 - 891 2015.12

Research paper (scientific journal), Joint Work, Accepted,  ISSN  1341-321X

　View Summary

The immunomodulatory activity of linezolid has recently been reported using in vitro experimental models. However, the anti-inflammatory activity of linezolid has not yet been demonstrated using in vivo experimental models. Therefore, the aim of the present study was to demonstrate the anti-inflammatory activity of linezolid and other anti-MRSA agents using the carrageenan-induced rat paw edema model.The pretreatment with 50 mg/kg linezolid significantly suppressed edema rates, compared with control (5% glucose), with edema rates at 0.5 and 3 h after the administration of carrageenan being 17.3 ± 3.5 and 30.8 ± 3.0%, respectively. On the other hand, edema rates were not suppressed by the pretreatments with 50 mg/kg vancomycin, teicoplanin, arbekacin, and daptomycin. Furthermore, we demonstrated that linezolid exhibited anti-inflammatory activity in a concentration-dependent manner. These effects were observed at linezolid concentrations that are achievable in human serum with conventional dosing.In conclusion, the results of the present study suggest that the anti-inflammatory activities of linezolid, in addition to its antimicrobial effects, have a protective effect against destructive inflammatory responses in areas of inflammation.

• Access to Document (DOI)

Pharmacokinetics of prophylactic ampicillin-sulbactam and dosing optimization in patients undergoing cardiovascular surgery with cardiopulmonary bypass.

Yuta Yokoyama, Kazuaki Matsumoto, Kazuro Ikawa, Erika Watanabe, HiroyukiYamamoto, Yutaka Imoto, Norifumi Morikawa, Yasuo Takeda.

BIOLOGICAL & PHARMACEUTICAL BULLETIN 38   1817 - 1821 2015.11

Research paper (scientific journal), Joint Work, Accepted,  ISSN  0918-6158

Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration-time curve in pediatric hematopoietic stem cell transplant recipients.

Erika Watanabe, Takuro Nishikawa, Kazuro Ikawa, Hiroki Yamaguchi, Takanari Abematsu, Shunsuke Nakagawa, Koichiro Kurauchi, Yuichi Kodama, Takayuki Tanabe, Yuichi Shinkoda, Kazuaki Matsumoto, Yasuhiro Okamoto, Yasuo Takeda, Yoshifumi Kawano.

INTERNATIONAL JOURNAL OF HEMATOLOGY 102   611 - 616 2015.11

Research paper (scientific journal), Joint Work, Accepted,  ISSN  0925-5710